Recipients of Syngeneic Marrow alone 
The charts of the last 10 syngeneic transplants performed for a variety of malignant diseases 
(ALL = 2, AML = 2, CML = 4, NHL = 1, Adeno Ca = 1) at the FHCRC were reviewed. These 
patients did not receive PBSC’s nor early post-transplant growth factors. One patient received M-CSF 
on day 30 for fungal infection and 2 patients received GM-CSF for graft failure on days 36 and 76. The 
latter patient, with CML in CP with mild myelofibrosis, received a second transplant for graft failure 
after a transient response to GM-CSF. One patient with CML in CP died on day 15 of regimen related 
complications and was unevaluable for engraftment. Engraftment data on the 9 evaluable patients are 
presented in Table V. 
Table V 
Engraftment in recipients of syngeneic marrow without PBSCs or growth factors 
Days 
Davs PosttransDlant to 
No. 
No. 
Spent 
Trans. 
Trans. 
ANC 
ANC 
ANC 
ANC 
PLTS 
of 
of 
<100 
>100 
>500 
>1000 
>20,000 
Pits 
RBCs 
Median 
(range) 
10 
(0-26) 
10 
(6-24) ' ' 
13 
(11-60) 
16 
(13450) 
32 
(14-56+) 
110 
(8-398) 
Six patients had positive blood cultures, 4 with Staph epi, 1 with Staph woneii, and 1 with streptomyces. 
The median day to discharge was 27 (19 - 99). Two of the 9 patients failed to achieve platelet 
independence; one requiring a second transplant for graft failure and 1 who relapsed on day 55. 
(4) Autologous Transplants with Growth Factor Mobilized PBSC’s. 
At this institution PBSCs have been mobilized with G-CSF or high dose Cy 
followed by GM-CSF. 
Two patients have received autologous transplants with G-CSF mobilized PBSC’s 
alone and 2 with PBSC’s collected after Cy and GM-CSF and G-CSF. Post- 
transplant growth factors were not administered. Prompt and sustained 
engraftment with a maximum follow-up of 6 months was achieved. Nine patients 
have received Autologous transplants with marrow and PBSC’s followed by post- 
transplant G-CSF and all have had durable engraftment. Table VI summarizes 
the engraftment data for these patients as well as for control populations not 
receiving PBSC’s. 
[364] 
Recombinant DNA Research, Volume 16 
